SANTA CLARA — When Isaac Guerendo trots onto the field with the first team Sunday at Levi’s Stadium, he will equal the same number of starts he had in five years of college football. Hard to believe, but Guerendo started exactly one time, and it came in his final college game at Louisville. Against USC in the Holiday Bowl, Guerendo carried 23 times for 161 yards and three touchdowns and added five receptions in a 42-28 loss. In 40 other games at Wisconsin and Louisville, Guerendo played in a shared backfield –something he’s done with the 49ers this season behind Jordan Mason and Christian McCaffrey . With McCaffrey on injured reserve with a PCL strain and Mason to follow soon with a high ankle sprain, Guerendo should get his biggest workload since his last college game. “I’m excited, but really it’s whatever it takes to win,” Guerendo said Wednesday as the 49ers (5-7) began preparations to host the Bears (4-8). “Whatever the plan looks like is what we’ll bring.” Guerendo will be backed up by Patrick Taylor Jr., who was on the roster earlier this season when McCaffrey was dealing with bilateral Achilles tendinitis, then re-signed to the practice squad. Taylor was promoted Tuesday, and the 49ers also made a waiver claim on former Jets running back Israel Abanikanda. “I think he’s ready to go,” 49ers coach Kyle Shanahan said. “He had some ups and downs but got better through everything. I think he’s ready for this.” Guerendo, 6-foot and 219 pounds, has 42 carries for 246 yards and two touchdowns, averaging a gaudy 5.9 yards per carry. His 15-yard run in the third quarter was the 49ers’ lone touchdown in a 35-10 loss to the Buffalo Bills. The 49ers traded up to get Guerendo in the fourth round, only to see him sidelined with a hamstring strain in his first training camp practice. A speedy wide receiver at Avon High School in Indiana who also ran track and played basketball, Guerendo carried 10 times for 99 yards with a long run of 76 against Seattle and 14 times for 85 yards against Dallas. At Wisconsin, Guerendo played behind Jonathan Taylor, now a star running back for the Indianapolis Colts. He split time as a graduate student at Louisville with Jawhar Jordan, who rushed for 1,128 yards while Guerendo had 810 yards on 132 carries and a 6.1-yard average. The good news is Guerendo’s body hasn’t taken on the normal amount of abuse for a running back. And Guerendo feels he’s up to the challenge after playing 12 games with old-school running backs coach Bobby Turner. “I always give credit to Coach T for preparing everybody like they’re going to be the starter, so that when moments do come, you’re ready for it,” Guerendo said. McCaffrey appeared to have finally gotten untracked against the Bills, gaining 53 yards on seven carries before getting tripped up on a 19-yard burst in the second quarter. But the tackle injured his knee, Mason injured his ankle, and Guerendo became the lead runner for a team that is sixth in the NFL in rushing. Over time, Guerendo has become accustomed to the speed of the NFL game. “I think it takes guys some time,” Shanahan said. “You start to get a feel for it, if you’ve got the right stuff, you get more reps and the more you adjust to it. How hard you’ve got to hit stuff, how quick those holes close, how you have to hit it full speed and can’t hesitate. We’ve seen that stuff get better in practice and we’ve seen it carry over into games.” McCaffrey, meanwhile, took to social media in the form of a lengthy Instagram post to explain how he was feeling after his latest injury. He wrote of his love for football, how humbling it is and his desire to return. “This wasn’t my year, and sometimes when it rains, it pours,” McCaffrey wrote. “You can feel sorry for yourself and listen to the birds, or you can hold the line. I’m grateful for the support of everyone in my corner and promise I’ll work smarter and harder to come back better from this.” For those who dream big, Shanahan said with a six-week time frame, McCaffrey could conceivably return if the 49ers reach the postseason. THE INJURY LIST Those who didn’t practice Wednesday included edge rusher Nick Bosa (hips, obliques), left tackle Trent Williams (ankle), left guard Aaron Banks (concussion), Mason (ankle) and linebacker Demetrius Flannigan-Fowles (ankle). Cornerback Deommodore Lenoir (knee), linebacker Dre Greenlaw (Achilles) and safety Talanoa Hufanga (wrist) were limited. Defensive tackle Jordan Elliott has cleared concussion protocol after missing the Buffalo game. Hufanga joined Greenlaw as practicing during a 21-day window. Shanahan said it’s more likely Greenlaw would be activated before a Thursday night game against the Los Angeles Rams on Dec. 12 than against Chicago. HUFANGA AND THE CLUB After recovering from an ACL tear last season, Hufanga has played in just two games this season. First, he was felled by an ankle injury, and then a wrist injury that needed surgery. When activated, he’ll play with a protective club on his right hand. “I was still dealing with the ankle. I was about to get it re-wrapped and for some reason my hand wouldn’t open,” Hufanga said. Hufanga said he’ll try to use the protective device as a benefit rather than a detriment. “I had a good friend back in the day who played with a club who had three picks in one game, so you never know,” Hufanga said. MOORE FARES WELL Left tackle Jaylon Moore acquitted himself well for the second straight game in starting in place of Williams. “It was OK, but you can always get better and that’s what I’m focusing on — the things I can get better at,” Moore said. Tight end George Kittle noted last week that Moore was at left tackle all through training camp during Williams’ holdout, so it’s not like he hasn’t been with the first team. “It definitely did help, especially being comfortable with the group,” Moore said. “The quarterback’s cadence, the guy you’re next to, all the small stuff comes into play.”With Assad’s ouster, Russia’s Mideast influence collapses. What will Moscow do now?
Limited social exposure, 'apprehensive' colleagues behind worsening work attitudes to disabled people: ExpertsInnovative AstroRad Vest Poised to Safeguard Astronauts from Space RadiationNBA Memo to Players Warns About Organized Home Break-InsNone
Patrick Soon-Shiong, the billionaire owner of the Los Angeles Times , declared this week that he will introduce an AI-generated “bias meter” alongside the newspaper’s opinion and news coverage as part of a broader effort to give its readers “both sides” of the story. The surprising move, which comes after he axed the paper’s planned endorsement of Kamala Harris and announced his intention to overhaul the Times’ editorial board to add more conservative voices, has prompted the paper’s union to publicly blast Soon-Shiong and longtime columnist Harry Litman to resign. Appearing on the podcast of right-wing CNN political commentator Scott Jennings, who is joining the Times’ editorial board, Soon-Shiong said he’s been “quietly building” the so-called bias meter “behind the scenes. Claiming that it will debut next month, the biotech entrepreneur said it uses the same artificial intelligence technology that he’s been developing at his other businesses for years. “Somebody could understand as they read it that the source of the article has some level of bias,” Soon-Shiong continued. “And what we need to do is not have what we call confirmation bias and then that story automatically — the reader can press a button and get both sides of that exact same story based on that story and then give comments.” Soon-Shiong’s remarks immediately drew an immediate rebuke from the LA Times’ union, which represents hundreds of journalists and newsroom staffers. “Recently, the newspaper’s owner has publicly suggested his staff harbors bias, without offering evidence or examples,” the guild’s council and bargaining committee said in a statement . “The statements came after the owner blocked a presidential endorsement by the newspaper’s editorial board, then unfairly blamed editorial board staffers for his decision.” The guild added that it had “secured strong ethics protections for our members, including the right to withhold one’s byline, and we will firmly guard against any effort to improperly or unfairly alter our reporting.” Litman, who had written for the Times for 15 years and been its senior legal columnist for the past three, announced on Thursday that he had tendered his resignation as a “protest and visceral reaction” against Soon-Shiong’s conduct as owner. “Soon-Shiong has made several moves to force the paper, over the forceful objections of his staff, into a posture more sympathetic to Donald Trump,” he wrote in a Substack post on Thursday. “Those moves can’t be defended as the sort of policy adjustment papers undergo from time to time, and that an owner, within limits, is entitled to influence.” Following Trump’s electoral victory, Soon-Shiong told CNN last month that he planned on “balancing” the paper’s editorial board with more conservative and centrist voices, complaining that it had “veered very left” in recent years. Following the owner’s polarizing decision to block the Times ’ Harris endorsement, which resulted in thousands of readers canceling their subscriptions, the board was reduced to just three members due to several resignations . Besides Litman and the LAT guild, roughly a dozen current and former Times staffers told media reporter Oliver Darcy that they felt “demoralized” by Soon-Shiong’s heavy-handed “meddling” in the newsroom. “The man who was supposed to be our savior has turned into what now feels like the biggest internal threat to the paper,” one staffer said. Additionally, Darcy explained why morale has plummeted at the paper in recent months — and much of it hinged on the owner’s apparent public embrace of Trump and MAGA, which they feel he is now looking to force the paper to reflect. “There certainly is plenty of cause to be alarmed. Soon-Shiong, who once fashioned himself as a Black Lives Matter-supporting vaccine proponent, has morphed into a Robert F. Kennedy Jr. and Jennings fanboy,” Darcy noted. “Since Trump’s victory in November, Soon-Shiong has turned to X to criticize the news media, praise Trump’s cabinet picks, and appeal to a MAGA audience. The change in behavior has confounded his journalists, who wonder what happened to the Soon-Shiong whose newspaper enforced strict Covid restrictions and emphasized its support for social justice causes.” The Independent has reached out to a Los Angeles Times spokesperson for comment.
Health insurance coverage rose by 40% in one year – NHIA
Biden weighs preemptive pardons for people on Trump’s enemies listDo you have a someone in your life who plays Vulture’s Cinematrix game every morning? Or maybe they have the kitchen television turned to Turner Classic Movies all day and make a point of organizing Oscar polls at work? Hate to break it to you: They might be a hard-to-please cinephile. But while you might not want to get into a winless debate over the “Juror No. 2” release or the merits of “Megalopolis” with said person, they don’t have to be hard to buy gifts for. The Associated Press has gathered up some of the best items out there to keep any movie lover stylish and informed. “Interstellar” 4K UHD While Christopher Nolan dreams up his next film, fans can tide themselves over by revisiting his modern classic “Interstellar,” which will be back in IMAX theaters on the weekend of Dec. 6, followed by the home release of a new collector’s edition on 4K Ultra HD and Blu-ray ($59.95). A third disc in the set, available Dec. 10, contains more than two hours of bonus content, like a never-before-seen storyboard sequence, and new interviews with Nolan, producer Emma Thomas and famous fans Peter Jackson and Denis Villeneuve. A biography of Elaine May Elaine May does not give interviews anymore. But thankfully that didn’t deter writer Carrie Courogen, who did a remarkable job stitching together the life of one of our culture’s most fascinating, and prickly, talents. “Miss May Does Not Exist” is full of delightful anecdotes about the sharp and satirical comedian who gained fame as one half of Nichols and May and went on to direct films like “The Heartbreak Kid” and “Mikey and Nicky.” Courogen writes about May’s successes, flops and her legendary scuffles with the Hollywood establishment. It’s a vital companion to Mark Harris’ biography of Mike Nichols. Macmillan. $30. A “Matrix” hoodie The Academy Museum of Motion Pictures has an exclusive new “Matrix” sweatshirt for sale in conjunction with its Cyberpunk exhibition. Brain Dead Studios designed and created several items, including the black hoodie ($140), a white rabbit tee ($54) and a pint glass ($18). An Academy Museum exhibition catalog If you can’t make it to Los Angeles to check out the “Color in Motion” exhibit for yourself, the Academy Museum also has a beautiful new companion book for sale ($55) charting the development of color technology in film and its impact. It includes photos from films like “The Red Shoes,” “Vertigo,” “2001: A Space Odyssey,” and images of rare prints from the silent era. The Academy Museum Store is having a sale (20% off everything) from Nov. 28 to Dec. 2. A status tote Want to look like a real film festival warrior, the kind who sees five movies a day, files a review and still manages to make the late-night karaoke party? You’re going to need the ultimate status tote from the independent streaming service MUBI. Simple, to-the-point and only for people in the know. $25. The Metrograph magazine Film magazines may be an endangered species, but print is not dead at The Metrograph. Manhattan’s coolest movie theater is starting a biannual print publication “for cinephiles and cultural connoisseurs alike.” The first issue’s cover art is by cinematographer Ed Lachman (“Carol”), and contributors include the likes of Daniel Clowes, Ari Aster, Steve Martin and Simon Rex. There’s also a conversation with Clint Eastwood. It’s currently available for pre-order and will be in bookstores Dec. 10 for $25 ($15 for Metrograph members). Director style This is not a book about filmmaking styles, camera angles and leadership choices. It’s literally about what directors wear. “How Directors Dress: On Set, in the Edit, and Down the Red Carpet” ($40) has over 200 archival photos of filmmakers in action: Spike Lee in his basketball caps, Sofia Coppola in her Charvet button-ups, Steven Spielberg’s denim on denim and many more. With a forward by the always elegant Joanna Hogg and writing from some of the top fashion journalists, it’s a beautiful look at how filmmakers really dress for work – and might even be a source of inspiration. ___ For more AP gift guides and holiday coverage, visit https://apnews.com/hub/gift-guide and https://apnews.com/hub/holidays.Meta to build $10 billion AI data center in Louisiana as Elon Musk expands his Tennessee AI facilityANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 [email protected] SOURCE TransMedics Group, Inc.
Union announce offseason roster moves, part with Leon FlachAP News in Brief at 6:04 p.m. EST
None